EA202190962A2 - EXPRESSION LEVELS OF IMMUNOGLOBULINS AS A BIOLOGICAL MARKER FOR THE RESPONSE TO THE PROTEASOME INHIBITOR - Google Patents

EXPRESSION LEVELS OF IMMUNOGLOBULINS AS A BIOLOGICAL MARKER FOR THE RESPONSE TO THE PROTEASOME INHIBITOR

Info

Publication number
EA202190962A2
EA202190962A2 EA202190962A EA202190962A EA202190962A2 EA 202190962 A2 EA202190962 A2 EA 202190962A2 EA 202190962 A EA202190962 A EA 202190962A EA 202190962 A EA202190962 A EA 202190962A EA 202190962 A2 EA202190962 A2 EA 202190962A2
Authority
EA
Eurasian Patent Office
Prior art keywords
subject
immunoglobulins
response
expression levels
proteasome inhibitor
Prior art date
Application number
EA202190962A
Other languages
Russian (ru)
Inventor
Брайан Тач
Джеремиа Дегенхардт
Андреа Лер
Кевин Квей
Кристофер Дж. Кирк
Original Assignee
Оникс Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оникс Терапьютикс, Инк. filed Critical Оникс Терапьютикс, Инк.
Publication of EA202190962A2 publication Critical patent/EA202190962A2/en

Links

Classifications

    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0631—Resource planning, allocation, distributing or scheduling for enterprises or organisations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Business, Economics & Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Human Resources & Organizations (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Strategic Management (AREA)
  • Economics (AREA)
  • Primary Health Care (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Game Theory and Decision Science (AREA)
  • Operations Research (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Theoretical Computer Science (AREA)
  • General Business, Economics & Management (AREA)
  • Oncology (AREA)

Abstract

В изобретении предоставлены способы лечения опухоли у субъекта и способы определения схемы лечения для субъекта с опухолью. В образцовых аспектах способы включают измерение уровня экспрессии иммуноглобулина, FCGR2B, гена, перечисленного в табл. 4, или их сочетания. В образцовых аспектах субъект представляет собой субъекта, у которого получали образец, где в образце измеряли уровень иммуноглобулина, FCGR2B, гена, перечисленного в табл. 4, или их сочетания. Кроме того, представлены связанные наборы, машиночитаемые запоминающие среды, системы и способы, реализуемые процессором в компьютере.The invention provides methods for treating a tumor in a subject and methods for determining a treatment regimen for a subject with a tumor. In exemplary aspects, the methods include measuring the expression level of an immunoglobulin, FCGR2B, of the gene listed in Table 1. 4, or combinations thereof. In exemplary aspects, the subject is a subject from whom a sample was obtained, where the level of immunoglobulin, FCGR2B, the gene listed in Table 1 was measured in the sample. 4, or combinations thereof. Also provided are associated sets, computer-readable storage media, systems, and methods implemented by a processor in a computer.

EA202190962A 2014-05-30 2014-08-08 EXPRESSION LEVELS OF IMMUNOGLOBULINS AS A BIOLOGICAL MARKER FOR THE RESPONSE TO THE PROTEASOME INHIBITOR EA202190962A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462005904P 2014-05-30 2014-05-30

Publications (1)

Publication Number Publication Date
EA202190962A2 true EA202190962A2 (en) 2022-02-28

Family

ID=54699954

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190962A EA202190962A2 (en) 2014-05-30 2014-08-08 EXPRESSION LEVELS OF IMMUNOGLOBULINS AS A BIOLOGICAL MARKER FOR THE RESPONSE TO THE PROTEASOME INHIBITOR

Country Status (3)

Country Link
EP (1) EP3149691A4 (en)
EA (1) EA202190962A2 (en)
WO (1) WO2015184427A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111107858A (en) * 2017-06-19 2020-05-05 美商生命科学公司 Treatment of sexual dysfunction and improvement of quality of sexual life
CN112101829B (en) * 2020-11-23 2021-02-19 广州赛太特生物医学科技有限公司 Management system and method for high-safety stem cell storage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040151706A1 (en) * 2003-01-27 2004-08-05 Alex Shakhov Collection and storage of biological specimens containing stem cells from healthy individuals for future use in treatment of their own cytopathological illnesses or other medical conditions
GB0322791D0 (en) * 2003-09-30 2003-10-29 Lifeforce Group Plc Blood co-processing for contingent autologous leukocyte transplantation
US20070166289A1 (en) * 2005-09-12 2007-07-19 Hathaway Alecia A Autologous human dna grafting - anti- & reverse aging process, method
EP2032691A2 (en) * 2006-06-15 2009-03-11 Neostem, Inc Processing procedure for peripheral blood stem cells
US8099297B2 (en) * 2007-01-22 2012-01-17 Hydrojoule, LLC Business method and system for ordering, purchasing and storing stem cells

Also Published As

Publication number Publication date
EP3149691A1 (en) 2017-04-05
WO2015184427A1 (en) 2015-12-03
EP3149691A4 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
EA201991105A1 (en) RISK ASSESSMENT METHODS USING TOTAL AND SPECIFIC NON-CELLULAR DNA
EA201890512A1 (en) METHODS OF TREATING PATIENTS WITH MALIGNANT TUMORS WITH THE USE OF PHARNESILTRANSFERASE INHIBITORS
CY1123259T1 (en) ANTI-PVRIG ANTIBODIES AND METHODS OF USE
EA201692157A1 (en) SYNTHESIS OF TWO-CELLULAR NUCLEIC ACIDS
EA201890926A1 (en) TRIAZOLE ACETHYL-COA-CARBOXYLASE INHIBITORS AND THEIR OPTIONS
EA202092665A3 (en) REGULATION OF GENE EXPRESSION THROUGH APTAMER-MEDIATED MODULATION OF ALTERNATIVE SPLICING
MA40682B1 (en) Anti-ox40 antibodies and methods of use thereof
EA201790984A1 (en) ANTI-CD79B ANTIBODIES AND METHODS OF THEIR APPLICATION
MX2016016902A (en) Methods of analyzing nucleic acids from individual cells or cell populations.
EA201491721A1 (en) CONNECTIONS AND METHODS OF KINAZ MODULATION AND INDICATIONS FOR THEIR APPLICATION
EA201691610A8 (en) ANTI-JAGGED1 ANTIBODIES AND METHODS OF APPLICATION
EA201692285A8 (en) EZH2 INHIBITORS FOR TREATING LYMPHOMA
EA201790769A1 (en) DETERMINATION OF THE LEVELS OF GLYCOSAMINOGLICANES BY THE MASS SPECTROMETRY METHOD
TR201909951T4 (en) A method for predicting the outcome of aflibercept treatment of a patient suspected of having cancer.
EA201992026A1 (en) APPLICATION OF BIOMARKERS IN THE IDENTIFICATION OF PATIENTS WHO CANCER WHICH WILL BE CHARACTERIZED BY THE PRESENCE OF TREATMENT WITH PRMT5 INHIBITOR
EA201790549A1 (en) PREDICTIVE AND PROGNOSTIC BIOMARKERS ASSOCIATED WITH ANTIANGIOGENIC TREATMENT OF MALIGNANT TUMOR
MX2019013953A (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer.
MX2022013471A (en) Nucleic acid detection and quantification method and compositions.
EA202091497A2 (en) GENETIC LOCUS ASSOCIATED WITH INCREASED FERTILITY IN MAIS
EA201891478A1 (en) METHODS AND COMPOSITIONS FOR RISK ASSESSMENT FOR CANCER
EA201790841A1 (en) GENES OF SUSTAINABILITY TO HERBICIDES AND METHODS OF THEIR APPLICATION
MX2016012278A (en) Early detection of preeclampsia.
AR104805A1 (en) METHODS AND COMPOSITIONS TO EVALUATE CANCER RESPONSE RESPONSE TO BET INHIBITORS
EA202190962A2 (en) EXPRESSION LEVELS OF IMMUNOGLOBULINS AS A BIOLOGICAL MARKER FOR THE RESPONSE TO THE PROTEASOME INHIBITOR
EA201491780A1 (en) C-RAF MUTANTS GIVING RESISTANCE TO RAF INHIBITORS